1398 Personalized immunotherapeutic platform with evidence of clinical activity in glioblastoma protects mice against ovarian liver and bladder cancer tumor challenges

Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy

“…Furthermore, T cells from mice receiving the murine version of IGV-001 produced IFNg in response to known tumor antigens from murine GL261 GBM cells [ 50 ]. Similar evidence of immunologic activity was seen in other mouse cancer models, including ovarian and urothelial cancers and hepatocellular carcinoma [ 50 , 60 , 61 ]. Together, these data strongly suggest that the use of this biologic-drug device product is a suitable approach to generate, contain, and release subcellular antigenic and immunogenic cargo to stimulate the immune system.…”

“…Studies conducted in syngeneic murine models support the use of the Goldspire ™ immunotherapy platform to treat a number of solid cancers beyond GBM. In the ID-8 murine ovarian carcinoma model (intraperitoneal, “metastatic-like”) [ 60 , 61 ], the Hepa1-6 murine hepatocellular carcinoma model (orthotopic) [ 50 , 62 ], and the MBT-2 murine bladder cancer model (orthotopic) [ 61 ], mice receiving a BDC prepared with the respective tumor cell line experienced significant prolongation of their mOS compared to mice implanted with saline-containing BDCs. These studies also demonstrated that the efficacy of this biologic-device combination product is associated with a systemic and durable immunological response, resulting in generation of Th1 antitumor cytotoxic T cells (unpublished data).…”